BAXTER INTERNATIONAL INC
BAXAPI behind this page
BAX Q2 2025 request
Playground key active
/api/financials?ticker=BAX&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue | 2,810 | 2,694 | +4.3% |
Show Product Lines breakouts |
|||
| Advanced Surgery · Medical Products & Therapies | 158 | 150 | +5.3% |
| Advanced Surgery · Medical Products & Therapies | 138 | 127 | +8.7% |
| Advanced Surgery · Medical Products & Therapies | 296 | 277 | +6.9% |
| Care & Connectivity Solutions · Healthcare Systems & Technologies | 341 | 332 | +2.7% |
| Care & Connectivity Solutions · Healthcare Systems & Technologies | 133 | 120 | +10.8% |
| Care & Connectivity Solutions · Healthcare Systems & Technologies | 474 | 452 | +4.9% |
| Drug Compounding · Pharmaceuticals | 280 | 261 | +7.3% |
| Drug Compounding · Pharmaceuticals | 280 | 261 | +7.3% |
| Front Line Care · Healthcare Systems & Technologies | 221 | 218 | +1.4% |
| Front Line Care · Healthcare Systems & Technologies | 72 | 78 | -7.7% |
| Front Line Care · Healthcare Systems & Technologies | 293 | 296 | -1.0% |
| Infusion Therapies & Technologies · Medical Products & Therapies | 554 | 579 | -4.3% |
| Infusion Therapies & Technologies · Medical Products & Therapies | 470 | 466 | +0.9% |
| Infusion Therapies & Technologies · Medical Products & Therapies | 1,024 | 1,045 | -2.0% |
| Injectables & Anesthesia · Pharmaceuticals | 187 | 197 | -5.1% |
| Injectables & Anesthesia · Pharmaceuticals | 145 | 144 | +0.7% |
| Injectables & Anesthesia · Pharmaceuticals | 332 | 341 | -2.6% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Non Us | 205 | 198 | +3.5% |
| Healthcare Systems & Technologies · Operating Segments | 767 | 748 | +2.5% |
| Healthcare Systems & Technologies · US | 562 | 550 | +2.2% |
| Medical Products & Therapies · Non Us | 608 | 593 | +2.5% |
| Medical Products & Therapies · Operating Segments | 1,320 | 1,322 | -0.2% |
| Medical Products & Therapies · US | 712 | 729 | -2.3% |
| Pharmaceuticals · Non Us | 425 | 405 | +4.9% |
| Pharmaceuticals · Operating Segments | 612 | 602 | +1.7% |
| Pharmaceuticals · US | 187 | 197 | -5.1% |
Show Geography breakouts |
|||
| Emerging Markets | 344 | 347 | -0.9% |
| Non Us | 1,274 | 1,202 | +6.0% |
| Non Us · Corporate Non Segment | 36 | 6 | +500.0% |
| Rest of world | 930 | 855 | +8.8% |
| US | 1,536 | 1,492 | +2.9% |
| US · Corporate Non Segment | 75 | 16 | +368.8% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 111 | 22 | +404.5% |
| Cost of Revenue | 1,819 | 1,663 | +9.4% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 388 | 380 | +2.1% |
| Medical Products & Therapies · Operating Segments | 755 | 734 | +2.9% |
| Pharmaceuticals · Operating Segments | 428 | 407 | +5.2% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Interest Rate Contract | 2 | — | — |
| Gross Profit | 991 | 1,031 | -3.9% |
| Research & Development | 134 | 130 | +3.1% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 49 | 46 | +6.5% |
| Medical Products & Therapies · Operating Segments | 63 | 55 | +14.5% |
| Pharmaceuticals · Operating Segments | 25 | 22 | +13.6% |
| Selling, General & Administrative | 718 | 723 | -0.7% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 222 | 202 | +9.9% |
| Medical Products & Therapies · Operating Segments | 295 | 293 | +0.7% |
| Pharmaceuticals · Operating Segments | 106 | 98 | +8.2% |
| Operating Income | 191 | 179 | +6.7% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 118 | 120 | -1.7% |
| Medical Products & Therapies · Operating Segments | 239 | 238 | +0.4% |
| Pharmaceuticals · Operating Segments | 64 | 75 | -14.7% |
| Reportable Segment · Operating Segments | 421 | 433 | -2.8% |
| Interest Expense | -14 | -18 | +22.2% |
| Other Non-Operating Income (Expense) (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | 3 | 1 | +200.0% |
| Income Before Taxes | 133 | 117 | +13.7% |
| Income Tax Expense (Benefit) | 11 | 22 | -50.0% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | 1 | — | — |
| Net Income | 91 | -314 | +129.0% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | 2 | — | — |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | 2 | 1 | +100.0% |
| Comprehensive Income | 287 | -420 | +168.3% |
| EPS (Basic) | 0.18 | -0.62 | +129.0% |
| EPS (Diluted) | 0.18 | -0.61 | +129.5% |
| Wtd Avg Shares (Basic) | 513 | 510 | +0.6% |
| Wtd Avg Shares (Diluted) | 514 | 511 | +0.6% |
| Operating Lease Lease Income | 87 | 82 | +6.1% |
| Other Expenses (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | -10 | — | — |
| Medical Products & Therapies · Operating Segments | -32 | 2 | -1700.0% |
| Pharmaceuticals · Operating Segments | -11 | — | — |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,686 | 1,574 | +7.1% |
| Accounts Receivable | 1,773 | 2,639 | -32.8% |
| Inventory | 2,384 | 2,985 | -20.1% |
| Prepaid Expenses & Other Current Assets | 906 | 874 | +3.7% |
| Total Current Assets | 6,749 | 8,593 | -21.5% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,802 | 4,314 | -35.0% |
| Goodwill | 5,395 | 6,001 | -10.1% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies | 3,570 | 3,981 | -10.3% |
| Medical Products & Therapies | 1,254 | 1,204 | +4.2% |
| Pharmaceuticals | 571 | 547 | +4.4% |
| Operating Lease Right-of-Use Assets | 289 | 524 | -44.8% |
| Other Non-Current Assets | 861 | 1,139 | -24.4% |
| Total Assets | 21,046 | 26,312 | -20.0% |
| Intangible Assets (Q) | — | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 2,404 | 2,640 | -8.9% |
| Developed technology, including patents | 922 | 1,355 | -32.0% |
| Other Intangible Assets | 20 | 18 | +11.1% |
| Trade Names | 817 | 891 | -8.3% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 4,950 | 5,741 | -13.8% |
| Current Liabilities | |||
| Short Term Borrowings | 6 | — | — |
| Long Term Debt And Capital Lease Obligations Current | 2 | 2,468 | -99.9% |
| Accounts Payable | 995 | 1,251 | -20.5% |
| Accrued Liabilities | 1,936 | 2,412 | -19.7% |
| Total Current Liabilities | 2,939 | 6,131 | -52.1% |
| Non-Current Liabilities | |||
| Operating Lease Liabilities | 225 | 439 | -48.7% |
| Other Non-Current Liabilities | 1,097 | 1,598 | -31.4% |
| Total Liabilities | 13,753 | 18,604 | -26.1% |
| Other Liabilities | |||
| Long Term Debt And Lease Obligation Excluding Current Maturities | 9,492 | — | — |
| Stockholders' Equity | |||
| Common Stock | 683 | 683 | 0.0% |
| Treasury Stock Common Value | -10,915 | -11,104 | +1.7% |
| Additional Paid In Capital Common Stock | 6,328 | 6,353 | -0.4% |
| Retained Earnings | 14,970 | 15,539 | -3.7% |
| Accumulated Other Comprehensive Income | -3,746 | -3,828 | +2.1% |
| Total Stockholders' Equity | 7,320 | 7,643 | -4.2% |
| Minority Interest | -27 | 65 | -141.5% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 7,293 | 7,708 | -5.4% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -480 | -449 | -6.9% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -111 | -109 | -1.8% |
| Accumulated Net Unrealized Investment Gain Loss | 3 | 3 | 0.0% |
| Accumulated Other Comprehensive Income | -3,746 | -3,828 | +2.1% |
| Accumulated Translation Adjustment | -3,158 | -3,273 | +3.5% |
| Additional Paid In Capital | 6,328 | 6,353 | -0.4% |
| Common Stock | 683 | 683 | 0.0% |
| Noncontrolling Interest | -27 | 65 | -141.5% |
| Parent | 7,320 | 7,643 | -4.2% |
| Retained Earnings | 14,970 | 15,539 | -3.7% |
| Treasury Stock Common | -10,915 | -11,104 | +1.7% |
| Total Liabilities & Equity | 21,046 | 26,312 | -20.0% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Net Income | 217 | -272 | +179.8% |
Show Equity Components breakouts |
|||
| Parent | 217 | -277 | +178.3% |
| Retained Earnings | 217 | -277 | +178.3% |
| Income Loss From Discontinued Operations Net Of Tax | 31 | -373 | +108.3% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -14 | — | — |
| Accumulated Translation Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -126 | — | — |
Show Disposal Group Classification breakouts |
|||
| Discontinued Operations Disposed Of By Sale | 31 | -373 | +108.3% |
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | 186 | 101 | +84.2% |
| Depreciation & Amortization | 504 | 498 | +1.2% |
| Deferred Income Taxes And Tax Credits | -165 | -92 | -79.3% |
| Stock-Based Compensation | 45 | 37 | +21.6% |
| Pension And Other Postretirement Benefits Expense Reversal Of Expense Noncash | -16 | -16 | 0.0% |
| Other Asset Impairment Charges | 24 | — | — |
| Other Non-Cash Items | 20 | 25 | -20.0% |
| Change in Accounts Receivable | -40 | 4 | -1100.0% |
| Change in Inventory | -279 | -172 | -62.2% |
| Change in Prepaid & Other Assets | 10 | -24 | +141.7% |
| Change in Accounts Payable | 21 | -5 | +520.0% |
| Increase Decrease In Accrued Expenses And Other Current Liabilities | -151 | -299 | +49.5% |
| Other Operating Activities Cash Flow Statement | -41 | -27 | -51.9% |
| Net Cash Provided By Used In Operating Activities Continuing Operations | 118 | 30 | +293.3% |
| Cash Provided By Used In Operating Activities Discontinued Operations | -94 | 248 | -137.9% |
| Net Cash from Operations | 24 | 278 | -91.4% |
| Investing Activities | |||
| Payments To Acquire Other Productive Assets | -262 | -180 | -45.6% |
| Payments To Acquire Intangible Assets | -9 | -4 | -125.0% |
| Other Investing Activities | 32 | 8 | +300.0% |
| Net Cash Provided By Used In Investing Activities Continuing Operations | -239 | -142 | -68.3% |
| Cash Provided By Used In Investing Activities Discontinued Operations | 3,389 | -115 | +3047.0% |
| Net Cash from Investing | 3,150 | -257 | +1325.7% |
| Financing Activities | |||
| Debt Repayments | -3,505 | -824 | -325.4% |
| Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less | -300 | — | — |
| Payments Of Dividends Common Stock | -174 | -295 | +41.0% |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 16 | 52 | -69.2% |
| Proceeds From Payments For Other Financing Activities | -25 | -9 | -177.8% |
| Net Cash from Financing | -3,988 | -1,076 | -270.6% |
| Supplemental | |||
| Unpaid Capital Expenditures (YTD) | — | — | — |
Show Property Plant And Equipment By Type breakouts |
|||
| Property Plant And Equipment | 39 | 44 | -11.4% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 88 | -47 | +287.2% |
| Net Change in Cash | -726 | -1,102 | +34.1% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 1,688 | 2,096 | -19.5% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,688 | 1,575 | +7.2% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.